This study will assess the long term safety for the use of tobramycin inhalation powder (TIP) in people with cystic fibrosis who have a chronic pulmonary infection with Pseudomonas Aeruginosa.

ELIGIBILITY

Age:

>= 6 Years

FEV1:

25 - 75 Percent Predicted

P. aeruginosa status:

Positive

B. cepacia status:

Negative

Other Primary Eligibility Requirements:

Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.

The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.